|
Characteristics of the FibroTest diagnostic studies for the staging of hepatic fibrosis in patients with chronic liver disease |
||||||||||||||||
| First author [ref] |
Number Patients |
Methodology |
Age |
Stage Prevalence |
AUROC SE |
F0 (%) |
F1 (%) |
F2 (%) |
F3 (%) |
F4 (%) |
DANA |
Size mm |
Independent |
Guidelines and fresh |
Biopsy FT median days |
High risk profile $ (%) |
|
|
||||||||||||||||
| HCV n = 20 |
||||||||||||||||
| Imbert-1, 2001 (21) |
189 |
Prospective Single center Training cohort |
47 |
F2F3F4 0.38 |
0.84 0.03 |
36 (18) |
91 (44) |
40 (20) |
18 (9) |
20 (10) |
2.03 |
16 |
No |
Yes |
0 |
NA |
| Imbert-2, 2001 (21) |
134 |
Prospective Single center Validation cohort |
48 |
F2F3F4 0.45 |
0.87 0.03 |
20 (15) |
54 (40) |
28 (21) |
10 (7) |
22 (16) |
2.16 |
16 |
No |
Yes |
0 |
NA |
| Poynard-1, 2001 (22) |
299 |
Retrospective Randomized trial Multicenter |
41 |
F3F4 Knodell 0.36 |
0.74 0.03 |
60 (20) |
133 (44) |
56** (17) |
55 (17) |
5 (2) |
1.42 |
NA |
Mixed |
Yes |
NA |
NA |
| Poynard-2, 2003 (23) |
352 |
Retrospective Randomized trial Multicenter Before treatment |
45 |
F2F3F4 0.39 |
0.73 0.03 |
6 (2) |
206 (59) |
63 (18) |
32 (9) |
32 (9) |
1.71 |
17 |
Mixed |
No |
137 |
0 (0) |
| Poynard-3, 2003 (23) |
352 |
Retrospective Randomized trial Multicenter After treatment |
47 |
F2F3F4 0.32 |
0.77 0.03 |
15 (4) |
222 (63) |
64 (18) |
25 (7) |
26 (10) |
1.73 |
17 |
Mixed |
No |
12 |
0 (0) |
| Rossi, 2003 (24) |
125 |
Prospective Multicenter |
40 |
F2F3F4 0.38 |
0.74 0.05 |
25 (20) |
52 (42) |
26 (21) |
13 (10) |
9 (7) |
1.95 |
NA |
Yes |
No |
0 |
0 (0) |
| Myers-1, 2003 (25) |
130 |
Retrospective Single center HCV-HIV Co-infection |
38 |
F2F3F4 0.45 |
0.86 0.04 |
17 (13) |
55 (42) |
22 (17) |
19 (15) |
17 (13) |
2.15 |
NA |
No |
Yes |
< 180 |
NA |
| Castera, 2005 (26) |
183 |
Prospective Single center |
51 |
F2F3F4 0.38 |
0.84 0.03 |
0 (0) |
47 (26) |
53 (29) |
37 (20) |
46 (25) |
1.95 |
17 |
Yes |
Yes |
0 |
NA |
| Cales-2, 2005 (7) |
120 |
Prospective Single center Validation cohort |
44 |
F2F3F4 0.48 |
0.86 0.06 |
20 (17) |
43 (36) |
28 (3) |
14 (12) |
15 (13) |
2.09 |
21 |
Yes |
No |
< 7 |
NA |
| Coletta, 2005 (27) |
40 |
Prospective Multicenter PNALT |
44 |
F2F3F4 0.35 |
NA |
3 (8) |
23 (58) |
9 (23) |
5 (13) |
0 (0) |
1.47 |
20 |
Yes |
NA |
180 |
NA |
| Varaut-1, 2005 (28) |
50 |
Retrospective Single center Dialysis patients |
48 |
F2F3F4 0.42 |
0.53 0.04 |
1 (2) |
28 (56) |
11 (22) |
8 (16) |
2 (4) |
1.61 |
19 |
Yes |
No |
< 180 |
2 (4) |
| Varaut-2, 2005 (28) |
60 |
Retrospective Single center Kydney recipients |
44 |
F2F3F4 0.44 |
0.71 0.04 |
10 (21) |
21 (35) |
17 (28) |
10 (16) |
2 (3) |
1.84 |
19 |
Yes |
No |
< 180 |
2 (3.3) |
| Halfon, 2006 (29) |
504 |
Prospective Multicenter |
45 |
F2F3F4 0.45 |
0.79 0.02 |
58 (12) |
216 (43) |
110 (22) |
91 (18) |
29 (6) |
1.87 |
15 |
Yes |
Yes |
0 |
15 (3) |
| Sebastiani-1, 2006 (30) |
65 |
Prospective PNALT |
45 |
F2F3F4 0.39 |
0.71 0.04 |
18 (27) |
22 (34) |
12 (19) |
6 (9) |
7 (11) |
2.21 |
18 |
Yes |
Yes |
0 |
Excluded |
| Sebastiani-2, 2006 (30) |
125 |
Prospective EALT |
50 |
F2F3F4 0.71 |
0.81 0.03 |
6 (5) |
30 (24) |
53 (42) |
15 (12) |
21 (17) |
1.83 |
18 |
Yes |
Yes |
0 |
Excluded |
| Wilson, 2006 * (31) |
115 |
Retrospective Multicenter 30% HIV |
42 |
F2F3F4 0.38 |
0.74 0.05 |
39 (33) |
36 (30) |
33 (28) |
8 (7) |
3 (3) |
1.87 |
11 |
Yes |
No |
Contemporaneous |
NA |
| Sene, 2006 (32) |
138 |
Prospective Single center Cryoglobulinemia Vasculitis |
58 |
F2F3F4 0.47 |
0.83 0.03 |
37 (27) |
36 (26) |
30 (22) |
16 (12) |
19 (14) |
3.05 |
18 |
No |
Yes |
< 60 |
11 (8) |
| Halfon-2, 2007 (36) |
158 |
Prospective Single center |
41 |
F2F3F4 |
0.79 0.03 |
6 (4) |
103 (65) |
34 (22) |
13 (8) |
2 (1) |
1.38 |
21 |
Yes |
Yes |
0 |
NA |
| Leroy, 2007 (37) |
180 |
Prospective Single center |
44 |
F2F3F4 |
0.84 0.03 |
15 (8) |
74 (41) |
40 (22) |
26 (14) |
25 (14) |
2.00 |
23 |
Yes |
Yes |
0 |
NA |
| Grigorescu, 2007 (39) |
206 |
Single center |
47 |
F2F3F4 |
0.78 0.02 |
16 (8) |
60 (29) |
70 (34) |
44 (21) |
16 (8) |
1.80 |
NA |
Yes |
Yes |
NA |
Excluded |
| HBV n = 4 |
||||||||||||||||
| Myers-2 (3) |
209 |
Prospective and (42) Retrospective (167) |
39 |
F2F3F4 0.29 |
0.78 0.04 |
76 (36) |
72 (34) |
32 (15) |
10 (5) |
19 (9) |
2.31 |
18 |
No |
Yes |
1 |
NA |
| Poynard-4, 2005 (4) |
214 |
Prospective |
40 |
F2F3F4 0.67 |
0.77 0.03 |
14 (8) |
53 (25) |
119 (24) |
55 (26) |
40 (19) |
2.17 |
NA |
Mixed |
Yes |
150 |
7 (3.2) |
| Sebastiani-3, 2007 (33) |
110 |
Prospective |
43 |
F2F3F4 |
0.85 0.04 |
15 (14) |
20 (18) |
40 (36) |
13 (12) |
22 (20) |
2.19 |
17 |
Yes |
Yes |
0 |
Excluded |
| Poynard-5, 2007 (34) |
924 |
Retrospective |
39 |
F2F3F4 |
0.76 0.02 |
21 (2) |
596 (65) |
160 (17) |
69 (7) |
78 (8) |
1.77 |
13 |
Mixed |
Yes |
90 |
80 excluded (8) |
| ALD n = 2 |
||||||||||||||||
| Naveau, 2005 (5) |
221 |
Prospective One center |
47 |
F2F3F4 0.64 |
0.84 003 |
16 (7) |
65 (29) |
48 (22) |
24 (11) |
68 (31) |
2.34 |
15 |
Mixed |
Yes |
9 |
4 (1.8) |
| Thabut, 2006 (35) |
208 |
Prospective Two centers |
51 |
F2F3F4 |
0.91 0.02 |
10 (5) |
25 (12) |
21 (10) |
17 (8) |
136 (65) |
2.98 |
12 |
Mixed |
Yes |
0 |
15 (7.2) |
| NAFLD n = 2 |
||||||||||||||||
| Ratziu-1, 2006 (8) |
170 |
Prospective |
53 |
F2F3F4 0.24 |
0.86 0.03 |
77 (45) |
54 (31) |
20 (12) |
11 (7) |
9 (5) |
2.30 |
20 |
No |
Yes |
0 |
5 (2.9) |
| Ratziu-2, 2006 (8) |
97 |
Prospective |
49 |
F2F3F4 0.15 |
0.75 0.04 |
26 (27) |
40 (41) |
15 (15) |
12 (12) |
4 (4) |
2.04 |
18 |
Yes |
Yes |
0 |
2 (2) |
| Mixed n = 3 |
||||||||||||||||
| Cales1, 2005 (7) |
478 |
Prospective Single center HCV, HBV, ALD |
45 |
F2F3F4 0.59 |
0.82 0.03 |
28 (6) |
170 (36) |
120 (25) |
57 (12) |
102 (21) |
2.08 |
18 |
Yes |
No |
< 7 |
NA |
| Callewaert, 2004 (6) |
106 |
Prospective HCV and ALD |
NA |
F4 0.29 |
0.89 0.04 |
0 (0) |
28 (26) |
20 (19) |
10 (9) |
48 (45) |
2.73 |
NA |
Yes |
Yes |
NA |
NA |
| Coco, 2007 (38) |
164 |
Prospective HCV and HBV |
50 |
F2F3F4 |
0.89 0.05 |
29 (18) |
33 (20) |
13 (8) |
6 (4) |
83 (51) |
3.15 |
25 |
Yes |
Yes |
90 |
NA |
|
*Details for stages given out of 119 and not out of 115: ** half of Knodell F3 has been counted as METAVIR F2 NA: not available; PNALT: persistently normal ALT; EALT: Elevated ALT $ High risk profile defined as hemolysis, Gilbert or acute inflammation; mean was 143/3,495 (4.1%) | ||||||||||||||||
Poynard et al. BMC Gastroenterology 2007 7:40 doi:10.1186/1471-230X-7-40 |
||||||||||||||||